China's booming biotech, from a brain implant to drug discovery
Summary
Science Friday explores China’s approval of the Neo brain-computer interface, with Wired’s Emily Mullen discussing its potential for paralysis patients and comparison to US rivals like Neuralink. The episode also features Georgetown’s Dr. Siyun Kang, who analyzes China’s rapid rise in the biotech sector, driven by efficient clinical trials and government investment. They examine how this shift impacts global pharmaceutical competition, drug pricing, and US-China scientific cooperation.
Topics discussed
Sponsors and show introduction
China approves first commercial brain-computer interface
How the Neo implant works compared to Neuralink
China's strategic investment in BCI technology
Real-world usability and calibration challenges
Sponsor breaks
The rise of China's biotech industry
Drivers of growth in Chinese drug development
Cost efficiency and clinical trial infrastructure in China
Global impact and talent retention concerns
Geopolitical risks and supply chain security
Drug pricing and future US-China cooperation
Listener call for AI in healthcare stories and credits
Listen ad-free on Castria